It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
We build expression strategies around your protein target, across host systems and production scales, to meet the unique needs of your research or drug discovery program.
Our approach is flexible, precise, and science-led, ensuring your project gets the right foundation from the start.
In our experience spending time on construct design, host cell selection and refining cell culture conditions is time well spent that ultimately leads to earlier delivery of a project. We have successfully used this approach to deliver a wide range of challenging protein targets including soluble, membrane and protein complexes at the quality and scale required for downstream research.
How we can assist you
We offer a comprehensive suite of protein construct design and expression services to support even the most complex discovery programs. Using advanced bioinformatics, diverse host systems, and cutting-edge bioreactor technologies, we deliver high-quality proteins tailored to your goals.
Protein Construct Design
We invest time upfront in construct design to avoid downstream issues and accelerate timelines. Every decision is made with the end use in mind, optimizing for purification efficiency and protein stability.
Protein Expression
Host systems
We work across E. coli (multiple strains), insect (Sf9, Sf21, Hi5), and mammalian (HEK293-6E, CHO-3E7, Expi293F) platforms.
Expression Screening & Culture Volumes
We run from 3 mL to 25 L as required. For larger volumes Wave bag reactors are available for insect and mammalian systems, and the Labforce5 bioreactor for E. coli.
Specialized Capabilities
• Uniform or specific isotopic labelling of proteins for NMR with 15N, 13C, and 2H
• Co-transformation or transfection as needed
• in vivo biotinylation via BirA co-expression across all platforms
Why Choose Sygnature Discovery for Protein Expression Support?
We take a tailored, science-first approach to protein expression, optimizing protocols to maximize for yield, quality, and scalability —even for hard-to-express proteins. Our teams have deep experience in boosting expression of biotherapeutics and isotopically labeled proteins. We perform small-scale construct scouting to identify the most promising candidates, including challenging membrane proteins. From multi-well plate screening to wave bag and fermentation systems, we ensure seamless scale-up for reliable, large-scale production.
Hear From One of our Experts
“Wi’ve um girt fowk’ wi cells, wi doa wha’ needs ta be done, ’n’ll sithee reet.”
Roughly translating from the Yorkshire, that reads along these lines…….
“At Sygnature Discovery we understand and value the contribution of every single member of our staff in being able to provide a premium Protein Science offering to our customers. Extending that analogy, our cells team are the foundation upon which everything else is built. Without them there would be nothing to purify protein from, nothing to characterize and we wouldn’t be able to elucidate beautiful protein structures”.
Our client needed a biotinylated version of a highly disordered protein for their high-throughput screening…
Case Studies
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
We treat every protein purification strategy on a case-by-case basis. Developing protocols to meet end use requirements. We particularly come into our own working with challenging protein targets.
Tailored bioscience solutions combining advanced technologies and collaborative expertise to design robust assays and accelerate confident drug discovery decisions.
We provide advanced biophysical techniques for protein identity, quality, and stability. Including mass spectrometry, FIDA, and NMR tailored to your research needs.
